|
AHA 2019: 11 Late Breaking Clinical Trials At-a-Glance
|
ICYMI: Straight from the 2019 AHA coverage of the recent Scientific Sessions, we offer snapshots of 11 newsmaking studies.
Read more
|
| |
| |
|
EVAPORATE: Icosapent Ethyl Added to Statins Slowed Coronary Atherosclerosis Progression
|
Early results from the EVAPORATE study suggest promise for icosapent ethyl as add-on therapy in patients with high TGs already taking statins.
Read more
|
| |
|
ORION: Twice-Yearly Inclisiran Halved LDL-C in ASCVD Patients on Statins
|
Semi-annual injection of the novel agent inclisiran in the ORION-10 trial decreased LDL-C by 56% in patients with ASCVD on maximal statin therapy.
Read more
|
| |
|
GALILEO: Rivaroxaban Caused Harm after TAVR
|
Post-TAVR use of rivaroxaban is not recommended for routine use among patients with no indication for anticoagulation.
Read more
|
| |
|
ISCHEMIA: Initial Revascularization Did Not Reduce Adverse CV Outcomes in SIHD
|
In SIHD patients with moderate-severe ischemia, initial revascularization + OMT compared to OMT alone did not reduce the risk for adverse CV outcomes.
Read more
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
